Evaluating adverse events after vaccination in the Medicare population

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 7, 2007, Pages 753-761

  Burwen, Dale R ^a   La Voie, Lawrence ^b   Braun, M Miles ^a   Houck, Peter ^c   Ball, Robert ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Centers for Medicare and Medicaid Services   (United States)

^c Centers for Medicare and Medicaid Services   (United States)

Author keywords

Adverse effects; Influenza vaccines; Medicare; Pharmacoepidemiology; Pneumococcal vaccines; Vaccines

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ABSCESS; ARTICLE; CELLULITIS; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; HOSPITALIZATION; HUMAN; MEDICARE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; URINARY TRACT INFECTION; VACCINATION;

ABSCESS; AGED; CELLULITIS; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; MEDICARE; PHARMACOEPIDEMIOLOGY; PNEUMOCOCCAL VACCINES; RISK FACTORS; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 34547541729     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1390     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. Surveillance summaries. MMWR 2003; 52(No. SS-1): 11-15.
2. Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23: 287-294.
3. Stratton KR, Howe CF, Johnston RB, Jr (eds). Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. National Academy Press: Washington, DC, 1994; 305-308.
4. Institute of Medicine. Immunization Safety Review. Available at http://www.iom.edu/project.asp?id=4705 (accessed on October 31, 2005).
5. Stratton K, Alamario DA, Wizemann T, McCormick MC (eds). Influenza Vaccines and Neurological Complications. National Academy Press: Washington, DC, 2004.
6. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 1997; 99: 765-773.
7. Centers for Medicare & Medicaid Services. Medicare enrollees, selected years, November 2003. Available at http://www.cms.hhs.gov/ researchers/pubs/datacompendium/2003/03pg30.pdf (accessed on October 31, 2005).
8. Population Division, U.S. Census Bureau. Table 2: annual estimates of the population by selected age groups and sex for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-02). Release date: June 9, 2005. Available at http://www.census.gov/popest/national/asrh/NC-EST2004/ NC-EST2004-02.xls (accessed on October 31, 2005).
9. Population Division, U.S. Census Bureau. Table 2: annual estimates of the population by sex and age for Puerto Rico: April 1, 2000 to July 1, 2004 (PRAS-EST2004-02 ). Release date: March 2005. Available at http://www.census.gov/popest/states/asrh/tables/SC-EST2004-02/ PRAS-EST2004-02.xls (accessed on October 31, 2005).
10. U.S. Census Bureau. The island areas. Available at http://www.census.gov/population/www/cen2000/islandareas.html (accessed on October 31, 2005).
11. Snow R, Babish JD, McBean AM. Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? Public Health Rep 1995; 110: 720-725.
12. Shih A, Quinley J, Lee TK, Messina CR. Assessing pneumococcal revaccination safety among New York State Medicare beneficiaries. Public Health Rep 2002; 117: 164-173.
13. Stratton K, Alamario DA, Wizemaun T, McCormick MC (eds). Influenza Vaccines and Neurological Complications. National Academy Press: Washington, DC, 2004; pp. 88-89.
14. Centers for Medicare & Medicaid Services. Privacy Act of 1974; Report of modified or altered system. Fed Reg 2002; 67: 3203-3210.
15. Centers for Medicare & Medicaid Services. Privacy Act of 1974; Report of modified or altered system. Fed Reg 2002; 67: 57015-57020.
16. Verstraeten T, DeStefano F, Chen RT, Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Rev Vaccines 2003; 2: 21-29.
17. Jackson LA, Carste BA, Malais D, Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J 2002; 21: 781-785.
18. Andrews NJ. Statistical assessment of the association between vaccination and rare adverse events post-licensure. Vaccine 2002; 20: S49-S53.
19. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectveness in seniors. Int J Epidemiol 2006; 35: 337-344.
20. Park T, Ki M, SG Y. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design. Statist Med 2004; 23: 1871-1883.
21. 2 tests. Biometrics 1954; 10: 417-451.
22. Agency for Healthcare Research and Quality. CAHPS®: surveys and tools to advance patient-centered care. Available at www.cahps.ahrq.gov (accessed on March 17, 2006).
23. Centers for Medicare & Medicaid Services. Medicare current beneficiary survey. Available at http://www.cms.hhs.gov/MCBS/ Default.asp (accessed on October 31, 2005).
24. Centers for Disease Control and Prevention. National Health Interview Survey. Available at http://www.cdc.gov/nchs/nhis.htm (accessed on October 31, 2005).
25. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. Available at http://www.cdc.gov/brfss/ (accessed on October 31, 2005).
26. Bonito AJ, Lenfestey NF, Eicheldinger C, Iannacchione VG, Campbell L. Disparities in immunizations among elderly Medicare beneficiaries, 2000 to 2002. Am J Prev Med 2004; 27(2): 153-160.
27. Centers for Medicare & Medicaid Services. FY 2005 GPRA Annual Performance Plan, FY 2004 Revised Final GPRA Annual Performance Plan, FY 2003 GPRA Annual Performance Report. January 2004. Available at http://www.cms.hhs.gov/GPRA/Downloads/PerformancePlan.pdf (accessed on 3/1/06).
28. Centers for Disease Control and Prevention. Table 4.1. Percentage of adults aged 50 years and older who received influenza vaccine during the past 12 months, by age, gender, and race/ethnicity: United States, 1997-2000. Available at www.cdc.gov/nchs/data/nhis/measure04.pdf (accessed on 12/29/05).
29. Federal Interagency Forum on Aging-Related Statistics. Table 21b. Percentage of people age 65 and over who reported having been vaccinated against influenza and pneumococcal disease, by selected characteristics, 2002. In Older Americans 2004: Key Indicators of Well-Being. Available at http://www.agingstats.gov/chartbook2004/ (accessed on 12/29/ 05).
30. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged >65 years - United States, 2001. MMWR 2002; 51: 1019-1024.
31. Centers for Disease Control and Prevention. Influenza vaccination coverage among adults aged ≥50 years and pneumococcal vaccination coverage among adults aged ≥65 years - United States, 2002. MMWR 2002; 52: 987-992.
32. Centers for Disease Control and Prevention. Table 5.1. Percentage of adults aged 65 years and older who had ever received pneumococcal vaccine: United States, 1997-2001. Available at www.cdc.gov/nchs/ data/nhis/measure05.pdf (accessed on 12/29/05).
33. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281: 243-248.
34. Pneumovax 23 (Merck) (Pneumococcal Vaccine Polyvalent) product labeling. December 2004.
35. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004; 22: 2064-2070.
36. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
37. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(No. RR-8): 1-24.
38. Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005; 40: 1730-1735.
39. Jackson LA, Nelson JC, Whitney CG, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006; 24: 151-156.
40. Whitney CG. New safety information for an old vaccine. Clin Infect Dis 2005; 40: 1736-1737.
41. Mullooly J, Drew L, DeStefano F, et al. Quality assessments of HMO diagnosis databases used to monitor childhood vaccine safety. Methods Inf Med 2004; 43: 163-170.
42. Bilker WB, Berlin JA, Gail MH, Strom BL. An efficient design for verifying disease outcome status in large cohorts with rare exposures and low disease rates. Statist Med 1999; 18: 3021-3036